Yuhan (000100.KS)

Executive Summary

Yuhan Corporation, founded in 1926, is South Korea's leading pharmaceutical company with a market capitalization exceeding $7.3 billion. The company boasts a diversified portfolio spanning ethical pharmaceuticals, consumer healthcare, and animal health, underpinned by robust R&D capabilities in small molecules, biologics, and drug delivery. Yuhan's open innovation model has driven development in oncology, metabolic diseases, and respiratory conditions, positioning it as a key player in Asian biotech. Its commercial success is supported by over 26 approved products, including generics and branded drugs for hypercholesterolemia and diabetic neuropathy. Recent pipeline highlights include the Phase 2 trial of Lesigercept for chronic spontaneous urticaria, which began enrollment in March 2026, and a Phase 3 trial for a parenteral nutrition product. Yuhan's strategic focus on innovative therapies, combined with its established commercial infrastructure, suggests continued growth. Upcoming catalysts, such as Lesigercept data readouts and potential licensing deals, could further enhance its valuation. However, early-stage pipeline risks temper near-term expectations.

Upcoming Catalysts (preview)

• Q4 2026Lesigercept Phase 2 Interim Data in Chronic Spontaneous Urticaria35% success
• H2 2026Potential Partnership or Licensing Deal for Oncology Asset45% success
• Q3 2026Phase 3 NTCB02-1 Completion and Regulatory Submission70% success